Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis

Summary

The purpose of this study is to determine the effectiveness and tolerability of a novel topical preparation for the treatment of cutaneous lesions of mastocytosis.

Timeline

Start

2021-07-26

Primary completion

2021-09-10

Completion

2021-09-10

Outcome

Outcome not reported

Stopped (Enrollment): “It was difficult to enroll patients during the pandemic. A new oral drug, Avapritinib, has since been approved for systemic mastocytosis. This medication controls skin manifestations of mastocytosis and is more convenient for patients to use.”

Drugs

Indications